Cervix Carcinoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Cervix Carcinoma

MalaCards integrated aliases for Cervix Carcinoma:

Name: Cervix Carcinoma 12 15 73
Carcinoma of Cervix 12 29 6
Carcinoma of the Cervix Uteri 12
Carcinoma Cervix Uteri 12
Cancer of Cervix 12


External Ids:

Disease Ontology 12 DOID:2893
NCIt 50 C9039
UMLS 73 C0302592

Summaries for Cervix Carcinoma

Disease Ontology : 12 A cervical cancer that is located in the cervix uteri or located in the cervical area and that has material basis in abnormally proliferating cells derives from epithelial cells.

MalaCards based summary : Cervix Carcinoma, also known as carcinoma of cervix, is related to cervix uteri carcinoma in situ and suppressor of tumorigenicity 3. An important gene associated with Cervix Carcinoma is FGFR3 (Fibroblast Growth Factor Receptor 3), and among its related pathways/superpathways are Cellular Senescence (REACTOME) and MAPK signaling pathway. The drugs Cisplatin and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include the cervix uteri or, cervix and testes, and related phenotypes are Decreased viability in esophageal squamous lineage and homeostasis/metabolism

Related Diseases for Cervix Carcinoma

Diseases related to Cervix Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 69)
# Related Disease Score Top Affiliating Genes
1 cervix uteri carcinoma in situ 31.7 CDKN2A FHIT TP53
2 suppressor of tumorigenicity 3 31.3 CDKN2A FHIT TP53
3 cervix small cell carcinoma 30.6 CDKN2A MAPK8IP1 MAPK8IP2 TP53
4 cervical cancer 29.7 CDKN2A FGFR3 FHIT HOXA11-AS STAT3 TP53
5 high-grade neuroendocrine carcinoma of the cervix uteri 12.3
6 glassy cell carcinoma of the cervix uteri 12.2
7 adenoid basal carcinoma of the cervix uteri 12.2
8 papillary carcinoma of the cervix uteri 12.2
9 cervical squamous cell carcinoma 11.0
10 cervical adenocarcinoma 11.0
11 primitive neuroectodermal tumor of the cervix uteri 11.0
12 non-invasive bladder papillary urothelial neoplasm 10.6 FGFR3 TP53
13 bladder papillary transitional cell neoplasm 10.6 FGFR3 TP53
14 urinary tract papillary transitional cell benign neoplasm 10.6 FGFR3 TP53
15 pleomorphic adenoma carcinoma 10.5 BECN1 TP53
16 ophthalmia neonatorum 10.4 MAPK8IP1 STYK1
17 sarcomatoid squamous cell skin carcinoma 10.4 MAPK8IP1 TP53
18 aging 10.4 FOXO3 STAT3 TP53
19 bladder urothelial carcinoma 10.3 FGFR3 FHIT TP53
20 brain stem astrocytic neoplasm 10.2 CDKN2A TP53
21 fallopian tube adenocarcinoma 10.2 MAPK8IP1 TP53
22 keratinizing squamous cell carcinoma 10.2 CDKN2A TP53
23 spitz nevus 10.1 CDKN2A TP53
24 skin carcinoma in situ 10.1 CDKN2A STAT3
25 bladder carcinoma in situ 10.1 CDKN2A TP53
26 bartholin's gland benign neoplasm 10.0 CDKN2A TP53
27 vulva squamous cell carcinoma 10.0 CDKN2A TP53
28 bone squamous cell carcinoma 10.0 CDKN2A STAT3 TP53
29 megaesophagus 10.0 CDKN2A FHIT TP53
30 gastric adenosquamous carcinoma 10.0 CDKN2A STAT3 TP53
31 thyroid lymphoma 10.0 CDKN2A TP53
32 barrett's adenocarcinoma 10.0 CDKN2A FHIT TP53
33 differentiated thyroid carcinoma 9.9 CDKN2A FHIT TP53
34 respiratory system cancer 9.9 CDKN2A STAT3 TP53
35 gastrointestinal system cancer 9.9 CDKN2A STAT3 TP53
36 cholangiolocellular carcinoma 9.9 ABCB1 CDKN2A
37 nasal cavity adenocarcinoma 9.9 CDKN2A TP53
38 larynx cancer 9.9 CDKN2A FHIT TP53
39 pancreas adenocarcinoma 9.9 CDKN2A STAT3 TP53
40 cervical carcinosarcoma 9.9 MAPK8IP1 MAPK8IP2 TP53
41 ameloblastic carcinoma 9.7 CDKN2A MAPK8IP2
42 bladder squamous cell carcinoma 9.7 CDKN2A FGFR3 TP53
43 brain glioma 9.6
44 vulva cancer 9.6
45 urinary tract obstruction 9.6
46 glioma 9.6
47 transitional cell carcinoma 9.6 CDKN2A FGFR3 TP53
48 burkitt lymphoma 9.6
49 thyroid carcinoma, familial medullary 9.6
50 lymphoma 9.6

Graphical network of the top 20 diseases related to Cervix Carcinoma:

Diseases related to Cervix Carcinoma

Symptoms & Phenotypes for Cervix Carcinoma

GenomeRNAi Phenotypes related to Cervix Carcinoma according to GeneCards Suite gene sharing:

# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.32 BECN1 CDKN2A CDKN3 DUSP3 FGFR3 FOXO3

MGI Mouse Phenotypes related to Cervix Carcinoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.25 SLC16A1 STAT3 MAPK8IP1 MAPK8IP2 TP53 NBN
2 behavior/neurological MP:0005386 10.24 TP53 NBN FOXO3 SLC16A1 MAPK8IP1 STAT3
3 endocrine/exocrine gland MP:0005379 10.16 NBN FOXO3 MAPK8IP1 STAT3 MAPK8IP2 TP53
4 digestive/alimentary MP:0005381 10.13 FOXO3 SLC16A1 STAT3 TP53 ABCB1 FGFR3
5 hematopoietic system MP:0005397 10.13 TP53 NBN FOXO3 STAT3 CDKN2A DUSP3
6 immune system MP:0005387 10.07 TP53 NBN FOXO3 STAT3 FOXM1 CDKN2A
7 mortality/aging MP:0010768 10.07 NBN FOXO3 SLC16A1 MAPK8IP1 STAT3 MAPK8IP2
8 liver/biliary system MP:0005370 9.87 TP53 SLC16A1 MAPK8IP1 STAT3 FOXM1 CDKN2A
9 neoplasm MP:0002006 9.81 STAT3 TP53 NBN FOXO3 FGFR3 BECN1
10 nervous system MP:0003631 9.65 NBN FOXO3 MAPK8IP1 STAT3 MAPK8IP2 TP53
11 reproductive system MP:0005389 9.32 FOXO3 MAPK8IP1 STAT3 MAPK8IP2 TP53 NBN

Drugs & Therapeutics for Cervix Carcinoma

Drugs for Cervix Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 468)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 15663-27-1 84093 441203 2767
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 437-38-7 3345
Ritonavir Approved, Investigational Phase 4,Phase 3,Phase 2 155213-67-5 392622
Diazepam Approved, Illicit, Investigational, Vet_approved Phase 4 439-14-5 3016
Meperidine Approved Phase 4 57-42-1 4058
Bupropion Approved Phase 4,Phase 2 34841-39-9, 34911-55-2 444
Dopamine Approved Phase 4,Phase 2 51-61-6, 62-31-7 681
Nicotine Approved Phase 4,Phase 1,Phase 2,Not Applicable 54-11-5 942 89594
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
Nevirapine Approved Phase 4 129618-40-2 4463
Aluminum hydroxide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 21645-51-2
Iron Approved Phase 4 7439-89-6 23925
Bethanechol Approved Phase 4 674-38-4 2370
Peppermint Approved, Nutraceutical Phase 4
Vitamin C Approved, Nutraceutical Phase 4,Phase 2 50-81-7 5785 54670067
16 Vaccines Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
17 Liver Extracts Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
18 Epoetin alfa Phase 4,Phase 3 113427-24-0
19 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
20 Adjuvants, Anesthesia Phase 4,Phase 3,Not Applicable
21 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Analgesics, Opioid Phase 4,Phase 3,Not Applicable
23 Anesthetics Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
24 Anesthetics, General Phase 4,Phase 3,Not Applicable
25 Anesthetics, Intravenous Phase 4,Phase 3,Not Applicable
26 Central Nervous System Depressants Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1
27 Narcotics Phase 4,Phase 3,Not Applicable,Early Phase 1
28 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
29 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
30 Hypoglycemic Agents Phase 4,Phase 2
31 Cytochrome P-450 Enzyme Inhibitors Phase 4,Phase 3,Phase 2
32 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
33 Psychotropic Drugs Phase 4,Phase 3,Phase 2
34 Anti-HIV Agents Phase 4,Phase 3,Phase 2,Phase 1
35 Anti-Retroviral Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1
37 Cytochrome P-450 CYP3A Inhibitors Phase 4,Phase 3,Phase 2
38 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1
40 Antibodies Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
41 Immunoglobulins Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
42 Fluorodeoxyglucose F18 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
43 Disinfectants Phase 4
44 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Polyhexamethylene biguanide Phase 4
46 Antidepressive Agents Phase 4,Phase 2
47 Antidepressive Agents, Second-Generation Phase 4,Phase 2
48 Cytochrome P-450 CYP2D6 Inhibitors Phase 4,Phase 2
49 Dopamine Agents Phase 4,Phase 2
50 Dopamine Uptake Inhibitors Phase 4,Phase 2

Interventional clinical trials:

(show top 50) (show all 1266)
# Name Status NCT ID Phase Drugs
1 Comparing Health Services Interventions for the Prevention of HPV-related Cancer Unknown status NCT02837926 Phase 4
2 Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China Unknown status NCT01021904 Phase 4
3 Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Unknown status NCT01101750 Phase 4
4 Can Alternative Treatment Have an Impact on Cervical Dysplasia? Unknown status NCT00842738 Phase 4
5 Influence of Gum Chewing on Postoperative Bowel Activity After Complete Staging Surgery for Gynecological Malignancies Unknown status NCT01835119 Phase 4 gum
6 Comparing the Rate of Insufficient Cells for Diagnosis Between Surepath® and Conventional Smear in Women After Radiation Therapy for Cervical Cancer Completed NCT01988376 Phase 4
7 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
8 Effect of HPV Vaccination on Women Aged 25 Years Completed NCT02296255 Phase 4
9 Patient Navigation in the Safety Net:CONNECTeDD Completed NCT00613275 Phase 4
10 V501 Safety and Efficacy Study in Japanese Women Aged 16 to 26 Years (V501-110) Completed NCT01544478 Phase 4
11 Delivery, Uptake and Acceptability of HPV Vaccination in Tanzanian Girls Completed NCT01173900 Phase 4
12 Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects Completed NCT00947115 Phase 4
13 Alternate Dosing Schedules Study for HPV Vaccine Completed NCT00862810 Phase 4
14 Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls Completed NCT00956553 Phase 4
15 Comparison of Meperidine and Fentanyl on Pain Scale and QOL in Brachytherapy Completed NCT02684942 Phase 4 Meperidine;Fentanyl
16 Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix TM) Administered in Healthy Adolescents Completed NCT00534638 Phase 4
17 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
18 Polyhexamethylene Biguanide Increases the Regression Rate of Human Papillomavirus (HPV) Infection Completed NCT01571141 Phase 4
19 Health Education Counseling With or Without Bupropion in Helping African Americans Stop Smoking Completed NCT00666978 Phase 4 bupropion hydrochloride
20 Counseling and Nicotine Replacement Therapy in Helping Adult Smokers Quit Smoking Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
21 The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies. Completed NCT03384511 Phase 4 Apatinib
22 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
23 Scientific Evaluation of One or Two Doses of the Bivalent or Nonavalent Prophylactic HPV Vaccines Recruiting NCT03180034 Phase 4
24 Transmission Reduction and Prevention With HPV Vaccination (TRAP-HPV) Study Recruiting NCT01824537 Phase 4
25 CervIcal Cancer Screening Trial by Randomization of HPV Testing Intervention for Upcoming Screening (CITRUS Study) Active, not recruiting NCT01895517 Phase 4
26 FASTER-Tlalpan Study Active, not recruiting NCT03105856 Phase 4
27 The Efficacy of Tachosil® for Prevention of Hemorrhage After Loop Electrosurgical Excisional Procedure (LEEP) Active, not recruiting NCT02629510 Phase 4 Tachosil
28 Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India Active, not recruiting NCT00923702 Phase 4
29 Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Active, not recruiting NCT01031069 Phase 4
30 Oral Iron vs. Placebo in Newly Diagnosed Gynecologic Oncology Patients Who Are Surgical Candidates. Active, not recruiting NCT01953107 Phase 4
31 Immunogenicity and Safety of Human Papilloma Virus Vaccine in Solid Organ Transplant Recipients Active, not recruiting NCT02624349 Phase 4 Quadravalent human papillomavirus vaccine
32 To Evaluate the Efficacy and Safety of PEG-rhG-CSF(Jinyouli®) in Reducing Neutropenia in Patients With Cervical Cancer Not yet recruiting NCT03206684 Phase 4 PEG-rhG-CSF;rhG-CSF
33 Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA Not yet recruiting NCT02910596 Phase 4 bethanechol chloride
34 Pilot Study to Assess the Potential Clinical Utility of 18F Fluciclovine PET for Cervical and Endometrial Cancer. Not yet recruiting NCT03423082 Phase 4 18F fluciclovine
35 Evaluation of Fluciclovine Uptake in Patients With Cervical, Ovarian Epithelial or Endometrial Cancers. Not yet recruiting NCT03349463 Phase 4 Fluciclovine F18
36 Dissemination of Cervical Cancer Screening to Primary Care Physicians in Underserved Communities Terminated NCT00629993 Phase 4
37 A Study to Assess the Safety and Reactogenicity of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (Cervarix) in Healthy Female Filipino Subjects Vaccinated According to the Prescribing Information From the Age of 10 Years Onwards. Terminated NCT00730847 Phase 4
38 Cisplatin Based Chemoradiation v.s Radiotherapy for Cervical Cancer and With Clinically Defined Good Prognosis Unknown status NCT00846508 Phase 3 Cisplatin
39 Randomized Trial Between Weekly and 5 Day 3 Weekly Cisplatin for Cervical Cancer Unknown status NCT00548821 Phase 3 Cisplatin
40 Study With Intensity Modulated Radiation Therapy With Cisplatin to Treat Stage I-IVA Cervical Cancer Unknown status NCT01554397 Phase 2, Phase 3 Cisplatin
41 Radiotherapy With Single-Agent Cisplatin or Combination Chemotherapy in Defined Poor-Prognostic Cervical Cancer Unknown status NCT00842660 Phase 3 Gemzar (gemcitabine)
42 Postoperative Chemoradiation v.s Radiotherapy for Lymph Node Negative Cervical Cancer Patients Unknown status NCT01756170 Phase 3 paclitaxel;cisplatin
43 Trial of Postoperative Chemoradiotherapy With or Without Consolidation Chemotherapy for Cervical Cancer Patients Unknown status NCT01755845 Phase 3 paclitaxel;cisplatin
44 Usefulness of FDG-PET for Advanced Cervical Cancer Unknown status NCT00146458 Phase 3
45 Comparing Study Between Concurrent Chemoradiation and New Combination Treatment in Cervical Cancer Patients Unknown status NCT01000415 Phase 3
46 Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment Outcome Unknown status NCT00348738 Phase 3 Erythropoietin
47 Hydralazine Valproate for Cervical Cancer Unknown status NCT00532818 Phase 3 Hydralazine and magnesium valproate;Placebo
48 IT-system Development for Reaching Cervix Cancer Screening Non-attenders Unknown status NCT02750124 Phase 2, Phase 3
49 Study on Paclitaxel Plus Topotecan in Comparison With Topotecan Plus Cisplatin in Recurrent or Persistent Cervical Carcinoma Unknown status NCT01405235 Phase 3 Paclitaxel;Cisplatin/Paclitaxel
50 Randomized Trial of Vaginal Self Sampling for Human Papillomavirus (HPV) Unknown status NCT01095198 Phase 2, Phase 3

Search NIH Clinical Center for Cervix Carcinoma

Genetic Tests for Cervix Carcinoma

Genetic tests related to Cervix Carcinoma:

# Genetic test Affiliating Genes
1 Carcinoma of Cervix 29 FGFR3

Anatomical Context for Cervix Carcinoma

The Foundational Model of Anatomy Ontology organs/tissues related to Cervix Carcinoma:

The Cervix Uteri Or

MalaCards organs/tissues related to Cervix Carcinoma:

Cervix, Testes, Lymph Node, Breast, T Cells, Lung, Colon

Publications for Cervix Carcinoma

Articles related to Cervix Carcinoma:

(show top 50) (show all 79)
# Title Authors Year
Increasing aggressiveness of patient-derived xenograft models of cervix carcinoma during serial transplantation. ( 29765518 )
Tanshinone IIA inhibits cervix carcinoma stem cells migration and invasion via inhibiting YAP transcriptional activity. ( 29909343 )
Paclitaxel dimers assembling nanomedicines for treatment of cervix carcinoma. ( 28359677 )
Dosimetric influence of filtered and flattening filter free photon beam on rapid arc (RA) radiotherapy planning in case of cervix carcinoma. ( 27790073 )
The induction of oxidative stress in cervix carcinoma cells by levoglucosenone derived 4-S-salicyl derivative and (1-4)-S-thio-disaccharides. Part 4. ( 28185719 )
DCE-MRI of patient-derived xenograft models of uterine cervix carcinoma: associations with parameters of the tumor microenvironment. ( 29100521 )
Extra-peritoneal laparoscopic para-aortic lymphadenectomy for staging of uterine cervix carcinoma. ( 28153518 )
Lymphoepithelioma-like carcinoma of cervix: Cytological Features on Conventional Cervical Smear. ( 28211234 )
Dosimetric study for cervix carcinoma treatment using intensity modulated radiation therapy (IMRT) compensation based on 3D intracavitary brachytherapy technique. ( 27504132 )
SU-F-T-62: Three-Dimensional Dosimetric Gamma Analysis for Impacts of Tissue Inhomogeneity Using Monte Carlo Simulation in Intracavitary Brachytheray for Cervix Carcinoma. ( 28048200 )
RGDS- and TAT-Conjugated Upconversion of NaYF4:Yb(3+)/Er(3+)&SiO2 Nanoparticles: In Vitro Human Epithelioid Cervix Carcinoma Cellular Uptake, Imaging, and Targeting. ( 27428386 )
Image-Guided High-Dose Rate Brachytherapy in Cervix Carcinoma Using Balloon Catheter and Belt Immobilization System. ( 26868850 )
Comparison of dosimetric parameters and acute toxicity of intensity-modulated and three-dimensional radiotherapy in patients with cervix carcinoma: A randomized prospective study. ( 27368915 )
STAT3:FOXM1 and MCT1 drive uterine cervix carcinoma fitness to a lactate-rich microenvironment. ( 26563366 )
Modulation of RhoA GTPase Activity Sensitizes Human Cervix Carcinoma Cells to I^-Radiation by Attenuating DNA Repair Pathways. ( 26649141 )
Systematic gene microarray analysis of the lncRNA expression profiles in human uterine cervix carcinoma. ( 26054679 )
Basaloid squamous cell carcinoma of cervix showing neuroendocrine differentiation. ( 26148627 )
Metastatic lobular carcinoma of breast mimics primary cervix carcinoma: two case reports and a review of the literature. ( 26435744 )
Evaluation of outcome and prognostic factors in 739 patients with uterine cervix carcinoma: a single institution experience. ( 26034391 )
The dosimetric impact of different photon beam energy on RapidArc radiotherapy planning for cervix carcinoma. ( 26865756 )
The association of GSTM1 and GSTT1 polymorphisms with squamous cell carcinoma of cervix in Pakistan. ( 25663492 )
Small cell neuroendocrine carcinoma of cervix and leiomyoma between the vagina and rectum. ( 25058833 )
Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy. ( 24666257 )
Cervix carcinoma and incidental finding of medullary thyroid carcinoma by 18F-FDG PET/CT--clinical case. ( 25088110 )
Synthetic racemates of abyssinone I and II induces apoptosis through mitochondrial pathway in human cervix carcinoma cells. ( 25019692 )
Peptidyl-prolyl isomerase Pin1-mediated abrogation of APC-I^-catenin interaction in squamous cell carcinoma of cervix. ( 24715170 )
Proteomic analysis reveals tanshinone IIA enhances apoptosis of advanced cervix carcinoma CaSki cells through mitochondria intrinsic and endoplasmic reticulum stress pathways. ( 24167031 )
Adenoid cystic carcinoma of cervix: treatment strategy. ( 24392415 )
A ROS-mediated lysosomal-mitochondrial pathway is induced by a novel Amonafide analogue, 7c, in human Hela cervix carcinoma cells. ( 23376642 )
Pulsed-dose-rate brachytherapy for uterine cervix carcinoma: 10 years of experience with 226 patients at a single institution. ( 23880416 )
Cervix carcinoma or Burkitt lymphoma metastases in meningiomas, two case reports. ( 23318021 )
Bladder-rectum spacer balloon in high-dose-rate brachytherapy in cervix carcinoma. ( 23517809 )
Ultrasound-assisted endocavitary HDR-Ir(192) brachytherapy for unresectable locally advanced uterine cervix carcinoma: retrospective analysis focusing the efficacy and tolerability. ( 22855184 )
Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study. ( 24074927 )
Concomitant boost plus large-field preoperative chemoradiation in locally advanced uterine cervix carcinoma: Phase II clinical trial final results (LARA-CC-1). ( 22425663 )
Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. ( 22633469 )
Uterine cervix carcinoma: recent biological data and update for improving follow-up and treatment. ( 23240379 )
Clinical behaviors and outcomes for adenocarcinoma or adenosquamous carcinoma of cervix treated by radical hysterectomy and adjuvant radiotherapy or chemoradiotherapy. ( 22365621 )
Hypoxia imaging of uterine cervix carcinoma with (18)F-FETNIM PET/CT. ( 22996235 )
Co-overexpression of bcl-2 and c-myc in uterine cervix carcinomas and premalignant lesions. ( 21556123 )
Primary stromal sarcoma of breast with malignant fibrous histiocytoma-like features causing diagnostic dilemma on fine-needle aspiration cytology in a patient with squamous cell carcinoma of cervix: a case report. ( 20607805 )
Long-term outcome and prognostic factors for adenocarcinoma/adenosquamous carcinoma of cervix after definitive radiotherapy. ( 20542643 )
A study on expression pattern of cyclooxygenase-2 in carcinoma of cervix. ( 22234093 )
Synergistic action of doxorubicin and sulindac in human cervix carcinoma cells - studies on possible mechanisms. ( 20037485 )
Low dynamin 2 expression is associated with tumor invasion and metastasis in invasive squamous cell carcinoma of cervix. ( 20574164 )
Psammoma bodies in cervical smear in association with keratinizing squamous cell carcinoma of cervix: a case report. ( 19217043 )
[The expression of RhoC and Ki67 in cervical intraepithelial neoplasia and squamous carcinoma of cervix]. ( 19462897 )
[Expression of P53, COX2 and CD44V6 in early-stage squamous carcinoma of cervix with lymph vascular space invasion positive and negative and its relationship with prognosis]. ( 20193563 )
Roscovitine up-regulates p53 protein and induces apoptosis in human HeLaS(3) cervix carcinoma cells. ( 18846503 )
Reactive oxygen species and nitric oxide regulate mitochondria-dependent apoptosis and autophagy in evodiamine-treated human cervix carcinoma HeLa cells. ( 18484413 )

Variations for Cervix Carcinoma

ClinVar genetic disease variations for Cervix Carcinoma:

# Gene Variation Type Significance SNP ID Assembly Location
1 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 GRCh37 Chromosome 4, 1803568: 1803568
2 FGFR3 NM_000142.4(FGFR3): c.746C> G (p.Ser249Cys) single nucleotide variant Pathogenic rs121913483 GRCh38 Chromosome 4, 1801841: 1801841

Expression for Cervix Carcinoma

Search GEO for disease gene expression data for Cervix Carcinoma.

Pathways for Cervix Carcinoma

GO Terms for Cervix Carcinoma

Cellular components related to Cervix Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.5 BECN1 CDKN2A FHIT FOXO3 MAPK8IP1 STAT3
2 nucleus GO:0005634 9.44 BECN1 CDC27 CDKN2A CDKN3 DUSP3 FGFR3

Biological processes related to Cervix Carcinoma according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription, DNA-templated GO:0045893 9.88 CDKN2A FOXM1 FOXO3 STAT3 TP53
2 negative regulation of apoptotic process GO:0043066 9.83 BECN1 FGFR3 MAPK8IP1 STAT3 TP53
3 response to drug GO:0042493 9.81 ABCB1 BECN1 FOXO3 STAT3
4 apoptotic process GO:0006915 9.73 BECN1 CDKN2A FGFR3 FHIT FOXO3 TP53
5 negative regulation of cell proliferation GO:0008285 9.72 BECN1 CDKN2A CDKN3 STAT3 TP53
6 glucose homeostasis GO:0042593 9.63 FOXO3 SLC16A1 STAT3
7 cell cycle GO:0007049 9.63 BECN1 CDKN2A CDKN3 FOXM1 NBN TP53
8 regulation of JNK cascade GO:0046328 9.52 MAPK8IP1 MAPK8IP2
9 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.49 FOXM1 TP53
10 replicative senescence GO:0090399 9.4 CDKN2A TP53
11 regulation of mitochondrial membrane permeability GO:0046902 9.37 STAT3 TP53
12 cell cycle arrest GO:0007050 9.26 CDKN2A CDKN3 NBN TP53
13 DNA damage response, signal transduction by p53 class mediator GO:0030330 8.8 FOXO3 NBN TP53

Molecular functions related to Cervix Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 transcription factor binding GO:0008134 9.56 CDKN2A NBN STAT3 TP53
2 protein phosphatase binding GO:0019903 9.33 CDC27 STAT3 TP53
3 protein kinase binding GO:0019901 9.28 BECN1 CDKN2A DUSP3 FOXM1 FOXO3 MAPK8IP1
4 MAP-kinase scaffold activity GO:0005078 8.96 MAPK8IP1 MAPK8IP2

Sources for Cervix Carcinoma

9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
55 Novoseek
58 OMIM via Orphanet
62 PubMed
70 SNOMED-CT via Orphanet
72 Tocris
74 UMLS via Orphanet
Loading form....